EPCAM and non-small cell lung carcinoma: The results show that the detection rate was 48.8% (20/41) using anti-EpCAM-MNs but 73.2% (30/41) using a combination of anti-EpCAM-MNs and anti-FRα-MNs, and a 24.39% higher CTC detection rate was achieved with a combination of EpCAM and FRα (p < 0.001) in the NSCLC patients.